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Abstract A large number of parameters have been
identified as predictors of early outcome in patients with
acute ischemic stroke. In the present work we analyzed a
wide range of demographic, metabolic, physiological,
clinical, laboratory and neuroimaging parameters in a large
population of consecutive patients with acute ischemic
stroke with the aim of identifying independent predictors of
the early clinical course. We used prospectively collected
data from the Acute Stroke Registry and Analysis of
Lausanne. All consecutive patients with ischemic stroke
admitted to our stroke unit and/or intensive care unit
between 1 January 2003 and 12 December 2008 within 24 h
after last-well time were analyzed. Univariate and multi-
variate analyses were performed to identify significant
associations with the National Institute of Health Stroke
Scale (NIHSS) score at admission and 24 h later. We also
sought any interactions between the identified predictors. Of
the 1,730 consecutive patients with acute ischemic stroke
who were included in the analysis, 260 (15.0%) were
thrombolyzed (mostly intravenously) within the recom-
mended time window. In multivariate analysis, the NIHSS
score at 24 h after admission was associated with the NIHSS
score at admission (b = 1, p \ 0.001), initial glucose level
(b = 0.05, p \ 0.002) and thrombolytic intervention
(b = -2.91, p \ 0.001). There was a significant interaction
between thrombolysis and the NIHSS score at admission
(p \ 0.001), indicating that the short-term effect of throm-
bolysis decreases with increasing initial stroke severity.
Thrombolytic treatment, lower initial glucose level and
lower initial stroke severity predict a favorable early clinical
course. The short-term effect of thrombolysis appears
mainly in minor and moderate strokes, and decreases with
increasing initial stroke severity.
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Introduction
Several prognostic models have been developed and vali-
dated to predict long-term outcome in patients with acute
stroke [1–4]. These indices include several variables
including age, the National Institute of Health Stroke Scale
(NIHSS) score, gender, prior stroke, diabetes mellitus and
fever. Such models provide prognostic information that
can be provided to the patient and family, and also help
clinicians in making decisions regarding treatment and
rehabilitation. However, fewer data are available regarding
the predictors of the early course following acute stroke
[5], and studies have been limited by a small sample size
or have involved the analysis of a limited number of
variables.
In the present study we analyzed a wide range of
demographic, metabolic, physiological, clinical, labora-
tory and neuroimaging parameters in a large population of
patients with acute ischemic stroke with the aim of
identifying independent predictors of the early clinical
course.
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Methods
We used prospectively collected data from the Acute
Stroke Registry and Analysis of Lausanne (ASTRAL) [6].
All consecutive patients who were admitted to the stroke
unit and/or intensive care unit of our hospital between 1
January 2003 and 12 December 2008 within 24 h of the
last-well time with a main diagnosis of acute ischemic
stroke were prospectively included. Recurrent strokes were
registered as new events if they led to a new admission.
Exclusion criteria included transient ischemic attack (TIA),
intracerebral hemorrhage, subarachnoidal hemorrhage,
cerebral sinus venous thrombosis and late admission
([24 h after stroke onset). Stroke severity at 24 h as
measured using the NIHSS score after admission was the
main outcome. Acute recanalization treatments were given
according to the recommendations of the European Stroke
Organization [7]: before the publication of ECASS-III [8],
intravenous thrombolysis given within 3 h and within 4.5 h
thereafter, and endovascular treatments within 6 h; these
patients were considered as treated ‘‘within the recom-
mended time window’’ in the current analysis. Symptom-
atic intracranial hemorrhage (sICH) within the first 24 h
was defined according to the ECASS-II criteria [9].
Stroke etiology was classified according to the TOAST
classification [10].
Demographic data (age, gender, ethnicity, insurance),
metabolic parameters (glucose, creatinine, cholesterol
levels), full blood count, physiological parameters (tem-
perature, heart rate, blood pressure) and the NIHSS score at
admission and 24 h after admission were prospectively
recorded for each patient. When possible, NIHSS scores
were determined by a NIHSS-certified stroke unit physician
who was not blinded to the treatment. When the NIHSS
scores were determined by a noncertified physician
(particularly during night and weekend duties), they were
discussed between the assessing and a NIHSS-certified
physician the next working day. In intubated patients,
NIHSS score determinations were in general performed
before intubation, and an effort was made to assess the
NIHSS score during a window without sedation. If more
than one blood pressure measurement was available at
admission or at 24–48 h, the first recording was registered.
Moreover, a systematic search was performed for every
patient to identify vascular risk factors including arterial
hypertension, atrial fibrillation, diabetes mellitus, val-
vulopathy, coronary artery disease and smoking. Also
recorded were prehospital Rankin score (mRS), previous
strokes, TIAs or retinal ischemia, as well as prior
medication. Finally, silent lesions, leukoaraiosis and early
ischemic changes on brain CT scans were recorded as well
as arterial stenosis/occlusion, since all patients underwent
brain parenchymal (mostly CT) and arterial (mostly CT
angiography) imaging. Extra- and/or intracranial stenosis of
[50% or occlusion of the arteries supplying the ischemic
territory was considered significant.
This study was approved by the ethics committee of our
institution and was therefore performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki.
Statistical analysis
In this retrospective analysis, heart rate, ejection fraction
and temperature were analyzed as categorical variables,
with the cut-off values at 90 min-1, 30% and 38C,
respectively. Blood pressure was analyzed as a continuous
variable. Laboratory values were analyzed as continuous
variables and are reported as median (interquartile range,
IQR). NIHSS scores at admission and 24 h later were
analyzed as continuous variables.
All parameters presented in Table 1 were included in a
univariate analysis to identify significant associations with
NIHSS score at 24 h after admission. The parameters
found to be of statistical significance (p \ 0.05) were
entered in a multivariate robust regression analysis model
to search for independent associations. The level of sig-
nificance was set at 95% (p = 0.05).
Results
Between 1 January 2003 and 12 December 2008, 3,165
patients with an acute ischemic stroke were admitted to the
stroke unit or intensive care unit. Of these, 1,435 (45.3%)
were excluded for the following reasons: intracerebral
hemorrhage (166 patients, 5.2%), TIA (577, 18.2%), late
admission (623, 19.7%), ocular ischemia (57, 1.8%) and
lack of NIHSS score at 24 h (12, 0.4%). Finally, 1,730
patients with acute ischemic stroke were included in our
analysis. Interestingly, 41% of patients had a prehospital
mRS of C1, probably due to the fact that we did not ana-
lyze only first-ever strokes, but also recurrences.
Table 1 summarizes the main demographic, clinical,
laboratory and imaging data of the patients. The median
NIHSS score was 6 (IQR 3–14) at admission and 4 (IQR
2–11) 24 h later. There was no interaction between NIHSS
score at admission and the infarct side. Thrombolysis was
performed within the recommended time limits in 260
patients (15.0%, of which 0.8% were acute endovascular
treatments), of whom 10 (3.8%) had a NIHSS score of 4,
none had a score of 3 and 1 (0.4%) had a score of 2. Only
one of the nonthrombolyzed patient and 5 (1.9%) of the
thrombolyzed patients suffered a sICH. The admission
NIHSS score of the patients with sICH was C21 in two
(33%), 16–21 in two (33%) and 10–15 in two (33%); no
J Neurol (2012) 259:524–529 525
123
patient with an admission NIHSS score B4 suffered
a sICH.
In the univariate analysis, 16 variables showed a sig-
nificant association with the NIHSS score at 24 h after
admission (Table 2). However, only initial stroke severity
(b = 1, p \ 0.001), glucose level (b = 0.05, p = 0.002)
and thrombolytic intervention (b = -2.91, p \ 0.001)
remained significant in the multivariate analysis. A sig-
nificant interaction (p \ 0.001) was identified between the
admission NIHSS score and intervention (Fig. 1). This
interaction was no longer statistically significant for NIHSS
scores of [21. This interaction remained significant after
excluding patients (a) with a low NIHSS score (B4),
(b) treated with intraarterial thrombolysis, and (c) with a
sICH. We also sought to determine whether this interaction
remained when the end-point was a favorable functional
outcome at 3 and 12 months (as represented by a mRS B2);
however, this was not the case, since thrombolysis was no
longer a significant predictor of outcome.
Discussion
Initial stroke severity, thrombolytic treatment and glucose
levels were correlated with the early neurological course as
measured by the NIHSS score at 24 h after admission. In
particular, thrombolytic intervention improved the early
clinical course in patients with minor and moderate strokes,
Table 1 Patient characteristics (n = 1,730)
Characteristic Value
Demographics
Age (years) 72 (60–81)
Female gender 766 (44.3%)
Last-well time to admission time (min)
Known-onset stroke 137 (87–198)
Unknown-onset stroke 753 (496–980)
Laboratory measurements (within 24 h of stroke onset)
Hemoglobin (g/l) 140 (129–151)
White blood cell count (9103/l) 8.1 (6.5–10.7)
Platelet count (9103/l) 225.0 (186–273)
Glucose (mmol/l) 6.5 (5.7–7.9)
Creatinine (mmol/l) 90 (75–107)
Total cholesterol (mmol/l) 5.4 (4.6–6.5)
Vital signs/Clinical examination (at admission)
Temperature (C) 36.4 (36.0–36.8)
Heart rate (min-1) 77.5 (67.7–90.0)
Systolic blood pressure (mmHg) 158 (140–178)
Diastolic blood pressure (mmHg) 89 (80–100)
NIHSS score B4 705 (40.6%)
NIHSS score [22 115 (6.6%)
Site of infarction
Right 717 (41.5%)
Left 836 (48.3%)
Bilateral 163 (9.4%)
Undetermined 14 (0.8%)
Arterial territory affected
Anterior circulation 1,074 (62.1%)
Vertebrobasilar circulation 502 (29%)
Both territories 21 (1.2%)
Undetermined 133 (7.7%)
Medical history/Previous treatment
Hypertension 1,151 (66.5%)
Atrial fibrillation 438 (25.3%)
Diabetes mellitus 233 (13.5%)
Newly diagnosed diabetes mellitus 30 (1.7%)
Prosthetic valve/mechanical/biological 58/45/13 (3.4%)
Coronary artery disease 262 (15.1%)
Smoking 411 (23.8%)
Previous stroke(s)/TIA(s) 462 (26.7%)
Antiplatelet treatment 655 (37.8%)
Antihypertensive agents 932 (53.7%)
Oral hypoglycemic agents 137 (7.9%)
Insulin 60 (3.5%)
Anticoagulant 171 (9.9%)
Lipid-lowering drugs 393 (22.7%)
Prestroke Rankin score 0 1,020 (59.0%)
Thrombolysis within recommended
time limits
Intravenous 246 (14.2%)
Table 1 continued
Characteristic Value
Intraarterial 14 (0.8%)
Symptomatic hemorrhagic transformation 5 (1.9%)
Imaging study findings
Silent lesions on brain CT scan 380 (22.0%)
Acute ischemic lesions on brain CT scan at
admission
531 (30.7%)
Leukoaraiosis 360 (20.8%)
Significant pathology on arterial imaging 668 (38.6%)
Stroke subtypes
Atherosclerotic ([50% stenosis) 218 (12.6%)
Possibly atherosclerotic (\50% stenosis) 252 (14.6%)
Cardioembolic 501 (29.0%)
Dissection 83 (4.8%)
Lacunar/microangiopathy 260 (15.0%)
Other/rare 68 (3.9%)
Multiple/coexisting 84 (4.9%)
Unknown 190 (11.0%)
Patent foramen ovale 67 (3.9%)
Categorical variables are presented as n (%). Continuous variables are
presented as median (interquartile range).
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but its effect decreased with increasing initial stroke
severity.
Currently, the upper NIHSS score for intravenous
thrombolysis as set by the European Medicines Agency is
25 [11], whereas the US Food and Drug Administration
states that the risks of treating acute ischemic stroke with
alteplase may be increased in patients with a severe neu-
rological deficit (NIHSS score[22) and should be weighed
against the anticipated benefits [12]. The rationale for this
recommendation is based on the fact that the safety and
efficacy of thrombolysis in patients with severe stroke have
not been tested in randomized controlled trials, since such
patients are usually excluded from thrombolysis trials. Our
findings from a stroke center which currently does not have
an upper exclusion limit for severe strokes, show that the
effect of thrombolysis decreases with increasing initial
stroke severity. Recently, an analysis of the Virtual Inter-
national Stroke Trials Archive (VISTA) has shown that the
significant association of outcome with thrombolysis is lost
if the baseline NIHSS score is C24, which the authors
attributed to small sample size and wide confidence inter-
vals [13]. Also, a high baseline NIHSS score was an
independent predictor of poor outcome in the Safe Imple-
mentation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) [14]. A subgroup analysis of the ECASS-III
trial [15] and a pooled analysis of the ATLANTIS, ECASS
and NINDS rTPA trials [16] did not provide strong evi-
dence to support exclusion of patients from treatment based
on their initial NIHSS score for any onset-to-treatment
interval; however, patients with a very severe stroke were
under-represented in these trials, therefore limiting the
amount of data from patients with a high NIHSS score.
Further studies are warranted to provide more reliable
conclusions.
In a recent analysis of the same dataset, we showed that
hyper- and hypoglycemia after stroke is deleterious in
acute ischemic stroke. We found a J-shaped association
between glucose and the 24-h and 12-month outcome [17].
The negative effect of hyperglycemia on short-term out-
come may be due to accelerated penumbra loss from high
glucose values [18, 19] and underlines the need to pay
particular attention to proper glucose management in acute
stroke. We failed to identify an association between initial
blood pressure and outcome. Previous studies have yielded
controversial results about the effect of blood pressure on
stroke severity and outcome [20]. Accordingly, it is still
Table 2 Uni- and multivariate
analysis of predictors of NIHSS
score at 24 h after admission
All parameters were assessed at
admission. Only significant
values are presented.
Variable Univariate analysis Multivariate analysis
b p value b p value
NIHSS score at admission 1 \0.001 1 \0.001
NIHSS score at 4–6 h 1 \0.001
Temperature 2.67 0.001
Heart rate 1.47 \0.001
Glucose 0.27 \0.001 0.05 0.002
C-reactive protein 0.11 \0.001
White cell count 0.54 \0.001
Hemoglobin -0.29 0.001
Red cell distribution width 0.24 0.01
Age 0.03 \0.001
Gender (female) -0.92 0.001
Prehospital Rankin score 1.03 \0.001
Atrial fibrillation 1.74 \0.001
Intervention 4.21 \0.001 -2.91 \0.001
Acute ischemic lesion on CT/MRI at admission 5.77 \0.001
Significant arterial pathology 5.27 \0.001
Fig. 1 Relationship between admission NIHSS score and 24-h
NIHSS score at a fixed level of acute glucose (dashed line
intervention patients, continuous line nonthrombolyzed patients)
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unclear whether its active treatment influences stroke out-
come, which is reflected by the level of recommendation in
the European Stroke Organisation and American Heart
Association/American Stroke Association guidelines on
stroke management [7, 21]. Several other well-known
predictors of early and late outcome, such as age, chronic
and early ischemic changes on neuroimaging, prehospital
disability, admission temperature, white cell count and
stroke mechanism were not confirmed in our sample; the
likely explanation is that most of these parameters were
predictors of the baseline NIHSS score in our population
(data not shown), which in turn predicted the NIHSS score
at 24 h after admission better than these factors themselves.
Also, we failed to identify an association between throm-
bolysis and outcome. We suggest that this may have been
due to the moderately small sample size of the study.
The strengths of our study include the large sample size
and the wide variety of analyzed parameters, including
demographic, clinical, metabolic, physiological, laboratory
and neuroimaging variables. In contrast, this study had
certain limitations. Firstly, we did not measure initial and
final infarct volume, which could have provided a deeper
insight into the pathophysiological basis of the reported
associations. Secondly, arterial status, recanalization and
stroke localization were not included in the current anal-
ysis. Thirdly, few of our patients received acute endovas-
cular treatments, limiting the possibility of detecting an
effect of different recanalization treatments. Finally, this
was an observational retrospective study and patients were
not randomized to treatment.
In conclusion, initial stroke severity, thrombolytic treat-
ment, and initial glucose values predict the early clinical
course over 24 h. Thrombolytic intervention improved
early clinical progression in patients with minor and mod-
erate stroke, but its effect decreased with increasing initial
stroke severity. According to these results, treatment
modalities other than standard intravenous thrombolysis
need to be explored in patients with severe stroke.
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